Abstract
Previous studies have shown that adding immune checkpoint inhibitor (ICI) to chemotherapy for extensive-stage small cell lung cancer (ES-SCLC) is effective and is currently the first-line treatment. However, there is no evidence whether it is effective as a second-line treatment after first-line chemotherapy and ICI combination therapy. Amrubicin is recommended as a second-line treatment for ES-SCLC in the guideline, and it is frequently used in Japan. Here, we report a retrospective study on the efficacy and safety of amrubicin as a second-line treatment for ES-SCLC after ICI therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
